Equities

Glaukos Corp

Glaukos Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)93.32
  • Today's Change0.63 / 0.68%
  • Shares traded74.79k
  • 1 Year change+88.30%
  • Beta1.0806
Data delayed at least 15 minutes, as of Mar 28 2024 16:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

  • Revenue in USD (TTM)314.71m
  • Net income in USD-134.66m
  • Incorporated1998
  • Employees907.00
  • Location
    Glaukos Corp1 GLAUKOS WAYALISO VIEJO 92656United StatesUSA
  • Phone+1 (949) 367-9600
  • Fax+1 (949) 367-9984
  • Websitehttps://www.glaukos.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Patterson Companies, Inc.6.57bn193.86m2.49bn7.60k13.702.588.890.37922.032.0368.8610.782.235.6114.48864,047.906.580.370211.300.565521.3021.052.950.18110.724312.080.4462846.10-0.42983.442.1410.798.220.00
Premier Inc1.32bn167.33m2.61bn2.80k15.641.098.881.981.391.3910.9719.950.35714.573.06470,033.204.4210.395.6713.0067.1362.0412.3722.601.32516.340.243119.11-6.762.44-34.17-15.30-2.29--
Helen of Troy Limited2.00bn162.04m2.73bn1.90k17.001.7212.971.366.766.7683.2766.810.65792.254.131,051,199.005.338.626.4610.8245.9543.168.109.720.97554.820.3168---6.786.98-35.97-0.48866.65--
Inari Medical Inc493.63m-1.64m2.75bn1.30k--5.89522.905.57-0.0318-0.03188.608.050.83781.577.67379,716.90-0.2777-0.5941-0.3129-0.669688.0389.06-0.3314-0.62952.52--0.00--28.73135.4094.41--52.46--
LivaNova PLC1.15bn17.55m3.01bn2.90k173.392.3644.422.610.32220.322221.3223.700.48832.765.79397,774.100.7472-6.010.8627-7.4266.8666.991.53-13.562.511.100.3147--12.890.8278120.34---1.64--
Enovis Corp1.71bn-54.37m3.41bn6.55k--0.997620.902.00-0.9987-0.611731.3362.610.38881.596.11260,640.80-1.23-0.3569-1.37-0.4158.2148.19-3.15-1.061.161.020.1199--9.22-4.89-40.29--11.91--
Axonics Inc366.38m-6.09m3.51bn797.00--5.49551.159.59-0.1285-0.12857.4312.560.53131.357.18459,697.60-0.8828-12.67-0.9601-13.7674.9470.04-1.66-29.688.98--0.00--33.86249.0689.80--23.65--
Envista Holdings Corp2.57bn-100.20m3.70bn12.80k--0.8855104.431.44-0.6022-0.602214.6524.340.38913.996.41200,507.80-1.521.94-1.792.3456.5257.65-3.905.291.905.120.26610.00-0.1012-2.04-142.10---4.22--
Integer Holdings Corp1.60bn90.65m3.84bn10.50k42.882.5220.282.412.682.6847.3045.580.55665.255.15152,064.103.163.283.433.5326.3026.945.686.401.713.540.38980.0016.035.6238.719.3321.71--
Lantheus Holdings Inc1.30bn326.66m4.14bn834.0013.035.0810.723.204.644.6418.5911.910.87239.465.211,554,471.0021.986.6925.757.7363.7153.9025.209.025.451,235.430.40810.0038.6530.441,063.8651.8135.48--
Haemonetics Corporation1.27bn126.57m4.27bn3.03k34.034.5319.413.362.472.4724.8018.570.62292.116.47418,649.006.214.747.055.8953.4849.779.977.411.7625.450.480.0017.675.27166.059.488.06--
Merit Medical Systems Inc1.26bn94.41m4.37bn6.95k46.643.6323.713.481.621.6221.5520.780.63042.367.34180,916.004.732.455.302.7746.4444.507.513.913.959.890.40640.009.247.3326.7015.86-11.16--
Glaukos Corp314.71m-134.66m4.59bn907.00--9.86--14.57-2.78-2.786.509.400.3241.898.29346,980.20-13.86-8.73-14.99-9.3575.9974.77-42.79-28.694.78-28.800.4335--11.2611.66-35.75--14.44--
Novanta Inc881.66m72.88m6.23bn2.90k85.929.2452.147.072.022.0224.4718.800.71473.046.36304,021.405.915.466.746.3445.3643.248.277.711.914.830.34770.002.417.49-1.588.214.19--
Inspire Medical Systems Inc624.80m-21.15m6.47bn1.01k--11.02--10.35-0.7298-0.729821.3219.371.014.228.27618,001.00-3.41-11.27-3.84-12.6084.5484.47-3.39-13.577.17--0.00--53.1965.3252.87--148.37--
Data as of Mar 28 2024. Currency figures normalised to Glaukos Corp's reporting currency: US Dollar USD

Institutional shareholders

57.60%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Dec 20237.29m14.73%
The Vanguard Group, Inc.as of 31 Dec 20235.10m10.31%
Fidelity Management & Research Co. LLCas of 31 Dec 20234.86m9.83%
Brown Capital Management LLCas of 31 Dec 20232.70m5.45%
SSgA Funds Management, Inc.as of 31 Dec 20231.82m3.67%
Janus Henderson Investors US LLCas of 31 Dec 20231.59m3.22%
Wellington Management Co. LLPas of 31 Dec 20231.34m2.71%
Invesco Advisers, Inc.as of 31 Dec 20231.32m2.66%
Weatherbie Capital LLCas of 31 Dec 20231.26m2.54%
Artisan Partners LPas of 31 Dec 20231.22m2.47%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.